Education
About Us
Working with TipRanks
Follow Us
Amy Schulman Insider Profile
4 Followers
Amy Schulman, Director at Alnylam Pharma, holds 11.96K shares in Alnylam Pharma (Ticker: ALNY), holds 8.55K shares in Fractyl Health, Inc. (Ticker: GUTS), holds 3.22M shares in SQZ Biotechnologies (Ticker: SQZB).
Profitable Transactions
1 out of 4 Profitable Transactions
Average Return
-29.20%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Amy Schulman holds in companies
Most Profitable Insider Trade
The most profitable trade made by Amy Schulman
Amy Schulman's Trading History
Alnylam Pharma
May 12, 2025
Director
Uninformative Buy
―
$4.77M
Blue Buffalo
Apr 24, 2018
―
Uninformative Sell
―
$0.00
Ironwood Pharma
Apr 03, 2019
Director
Uninformative Sell
―
$122.76K
X4 Pharmaceuticals
―
Director
―
―
Cyclerion Therapeutics
Apr 10, 2019
Director
Informative Buy
10.02M
$906.08K
SQZ Biotechnologies
Dec 23, 2021
Director, Ten Percent Owner
Uninformative Buy
84.82K
$77.33K
Fractyl Health, Inc.
Mar 17, 2025
Director
Informative Buy
9.92K
$19.32K
DNIB Unwind, Inc.
―
―
―
$0.00
Pfizer
May 16, 2013
Former Exec. Vice President
Uninformative Sell
2.06M
$5.65M
Zoetis
Feb 08, 2013
Director
Informative Buy
130.00K
$617.70K
List of latest transactions for each holding click on a transaction to see Amy Schulman's performance on stock
You May Also Like
Amy Schulman insider profile FAQ
What is the percentage of profitable transactions made by Amy Schulman?
The percentage of profitable transactions made by Amy Schulman is 25%.
What is the average return per transaction made by Amy Schulman?
The average return per transaction made by Amy Schulman is -29.20%.
What stocks does Amy Schulman hold?
Amy Schulman holds: ALNY, BUFF, IRWD, XFOR, CYCN, SQZB, GUTS, BINDQ, PFE, ZTS stocks.
What was Amy Schulman’s latest transaction?
Amy Schulman latest transaction was an Uninformative Buy of ―.
What was Amy Schulman's most profitable transaction?
Amy Schulman’s most profitable transaction was an Informative Buy of GUTS stock on March 17, 2025. The return on the trade was 73.20%.
What is Amy Schulman's role in Alnylam Pharma?
Amy Schulman's role in Alnylam Pharma is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.